Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
USP7
REST API REST API
Homo sapiens
USP7 is differentially expressed in 310 experiments: 152 organism parts: amygdala, testis, ... (150 more);, 230 disease states: normal, prostate carcinoma, ... (228 more);, 92 cell types 474 cell lines 44 compound treatments and 80 other conditions.
Synonyms HAUSP
Orthologs F1N909_CHICK (Gallus gallus)   Usp7 (Rattus norvegicus)   F1N556_BOVIN (Bos taurus)   usp7 (Danio rerio)   F6YGH8_CIOIN (Ciona intestinalis)   UBP15 (Saccharomyces cerevisiae)   Usp7 (Mus musculus)   Usp7 (Drosophila melanogaster)   usp7 (Xenopus laevis)   USP7 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cytoplasm, ubiquitin thiolesterase activity, peptidase activity, regulation of protein stability, ubiquitin-specific protease activity, transcription factor binding, induction of apoptosis, multicellular organismal development, cysteine-type endopeptidase activity, protein deubiquitination, nucleus, protein homodimerization activity, hydrolase activity, protein C-terminus binding, cysteine-type peptidase activity, ubiquitin-dependent protein catabolic process, ubiquitin protein ligase binding, interspecies interaction between organisms, PML body, p53 binding, regulation of sequence-specific DNA binding transcription factor activity
InterPro Term Peptidase_C19, MATH, Pept_C19_dom
UniProt Accession Q93009, B7Z815, B7Z7T5, F5H8E5, F5H2X1
Search EB-eye ENSG00000187555
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-TABM-34, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
Jurkat
3
E-MEXP-2197, E-MTAB-62, E-GEOD-1880
A549
2
E-GEOD-3202, E-GEOD-6013
HCC2157
2
E-MTAB-37, E-MTAB-62
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
T84
2
E-MTAB-37, E-GEOD-1474
468 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (48 experiments)

Factor Value U/D Experiments
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
CD33+ myeloid
1
E-AFMX-5
chondrocyte
1
E-TABM-130
endothelial cells and pericytes
1
E-MEXP-1251
naive T cell
1
E-GEOD-1460
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MTAB-62, ... (60 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
prostate carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-MEXP-2034, E-MEXP-1327
control
2
E-GEOD-20602, E-GEOD-8121
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
224 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5258, E-GEOD-1417, E-GEOD-697, E-TABM-782, ... (27 experiments)

Factor Value U/D Experiments
none
3
9
E-GEOD-5824, E-GEOD-412, E-MEXP-1958, E-GEOD-995, E-GEOD-5099, ... (12 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
17beta-estradiol
5
1
E-GEOD-4668
control for heregulin
1
E-GEOD-6462
unknown
1
E-GEOD-7307
38 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (8 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-MEXP-1437, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-GEOD-21612, E-GEOD-20540, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.487 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM